
    
      This is a post-marketing, non-interventional study of participants with moderate to severe
      UC. The study will review medical records of participants who have initiated medical
      treatment with vedolizumab intravenous during the defined eligibility period under routine
      clinical practice to provide the real world data on the effectiveness and safety of
      vedolizumab intravenous.

      The study will enroll approximately 100 participants. All participants will be enrolled in
      one observational group: Vedolizumab

      Both retrospective and prospective data will be collected in the index period, with
      prospective data collected for treatment baseline visit and follow up visits.

      The multi-center trial will be conducted in Republic of Korea. The overall duration of study
      will be approximately 15 months.
    
  